Trial reportBMC anesthesiology2026
Esketamine-augmented stellate ganglion block improves postoperative sleep quality after gynecological laparoscopic surgery: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPostoperative sleep disturbance (PSD) is common after gynecological laparoscopic surgery and is associated with delayed recovery and adverse emotional outcomes. Stellate ganglion block (SGB) and esketamine have each been reported to modulate perioperative stress responses. We hypothesized that adding an esketamine-adjuvanted SGB to a perioperative multimodal sleep (PMS) strategy based on intraoperative esketamine and dexmedetomidine would reduce PSD.
methodsIn this prospective randomized controlled trial, 220 of 222 screened patients scheduled for elective gynecological laparoscopic surgery were randomized and assigned to either a control group receiving intraoperative esketamine and dexmedetomidine or an intervention group receiving an esketamine-adjuvanted SGB before anesthesia induction in addition to the same intraoperative regimen. The primary outcome was the incidence of PSD on postoperative days 1 and 3. Secondary outcomes included postoperative anxiety and depression, pain intensity, use of rescue medication, and perioperative complications.
resultsA total of 192 patients were included in the per-protocol (PP) analysis. The incidence of PSD was significantly lower in the intervention group than in the control group on postoperative day 1 (62.9% vs. 83.2%, P = 0.002) and postoperative day 3 (25.8% vs. 42.1%, P = 0.017). The intervention group also exhibited a lower incidence of early postoperative anxiety. In subgroup analyses, the intervention was associated with a significantly lower incidence of PSD in patients with preoperative depressive symptoms. Independent risk factors for PSD included preoperative sleep disturbance, preoperative anxiety, resting pain, abdominal drainage tube placement, and total hysterectomy. No significant differences in adverse events were observed between the two groups.
conclusionsIn this single-center randomized trial, adding an esketamine-adjuvanted stellate ganglion block to intraoperative esketamine and dexmedetomidine was associated with a lower incidence of postoperative sleep disturbance after gynecological laparoscopic surgery, without an apparent increase in perioperative complications. These findings require confirmation in larger multicenter studies incorporating objective sleep assessments.
trial registrationThis study was registered in the Chinese Clinical Trial Registry (ChiCTR2300078436) on December 8, 2023.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.